Comments
Shilpa Medicare Ltd has received without 483 for its SEZ formulations facility situated at Jadcherla near Hyderabad from the United States Food & Drug Administration (USFDA).
USFDA’s 483 is a form issued to a company or management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
The company had said USFDA conducted audit from July 18 to 26.
The company shares were trading higher by 5.77 per cent at Rs 592.80 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.